WEDNESDAY, Sept. 18, 2024 (HealthDay News) — Cutaneous head and neck melanoma (CHNM) has a distinct clinicopathological and prognostic profile relative to cutaneous melanomas of other sites (CMOS), according to a study published online Sept. 5 in the Journal of the American Academy of Dermatology.
2024
Assessing New RAF-Directed Drugs in Melanoma
Data from the phase I KN-8701 trial suggest that combining exarafenib, an investigational pan-RAF inhibitor, with the MEK agent binimetinib is a reasonable second-line option for NRAS-mutant melanoma.
Hensin Tsao, MD, PhD: TIL Therapy and Neoadjuvant Treatment for Pigmented Lesions
In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical clinical presentation.
Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.